Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Novanta reported third-quarter GAAP revenue of $305 million, up 23%, while Adjusted EBITDA rose 38% to $80 million. It expects full-year 2026 GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
- 10-Q report · filed Nov 9, 2026
- Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.
The audio replay and transcript follow the call.